Core Viewpoint - Amgen (AMGN) is expected to exceed earnings expectations for Q2 2025, with consensus estimates for sales at $8.86 billion and earnings per share at $5.25, following a previous quarter where it beat earnings expectations by 17.8% [2][9]. Sales Performance - Strong volume growth from products such as Evenity, Repatha, and Blincyto is anticipated to drive sales, although prices are expected to decline due to increased rebates [3][9]. - The Zacks Consensus Estimate for sales of Evenity, Repatha, and Blincyto is $478 million, $673 million, and $385 million, respectively [3]. Product Insights - Sales of RANKL antibodies, Prolia, and Xgeva are expected to benefit from volume growth, despite price declines. However, the expiration of patents for Prolia and Xgeva in the U.S. in February 2025 may lead to significant sales erosion in the latter half of 2025 [5]. - Newer drugs like Tezspire and Tavneos are projected to contribute positively to top-line growth, with consensus estimates of $320 million and $102 million, respectively [6]. Competitive Landscape - Kyprolis is facing competitive pressure, which likely affected its volume growth in Q1 and is expected to continue in Q2, with consensus estimates for sales at $370 million [7]. - Enbrel sales are likely to decline due to lower prices, while Otezla is expected to see gains from volume growth, with estimates of $534 million for Otezla and $805 million for Enbrel [8]. Recent Developments - Sales of rare disease drugs from the acquisition of Horizon are expected to improve in Q2, following lower-than-expected sales in Q1 due to inventory changes [10]. - New biosimilars launched, such as Wezlana and Pavblu, are anticipated to drive sales growth, although fluctuations in quarterly sales are expected [12][13]. Earnings Surprise History - Amgen has a strong earnings surprise history, with an average surprise of 8.34% over the last four quarters and a stock increase of 18.4% year-to-date compared to a 1.9% increase in the industry [14]. Earnings Prediction Model - The earnings prediction model indicates a likely earnings beat for Amgen, with an Earnings ESP of +1.19% and a Zacks Rank of 3 [15][17].

Core Insights - The Medical sector is experiencing a robust first-quarter earnings season, with several drugmakers reporting results, and large caps like J&J, Merck, and Amgen exceeding earnings and sales estimates [1][2] - Overall, first-quarter earnings for the Medical sector are projected to rise by 40%, with revenues expected to increase by 8.3% [3] Earnings Performance - As of April 30, 45% of Medical sector companies, representing approximately 57.9% of the sector's market capitalization, have reported earnings, with 66.7% beating both earnings and revenue estimates [2] - Year-over-year earnings growth for the sector is reported at 60.5%, while revenues have increased by 7.8% [2] Company Highlights - **Novo Nordisk**: Expected to report earnings of 92 cents per share and revenues of $11.33 billion, with strong sales anticipated from diabetes and obesity care products [6][7] - **Pacira BioSciences**: Projected earnings of 57 cents per share and revenues of $174.96 million, driven by sales of its pain-management product Exparel [8][9] - **Ultragenyx Pharmaceuticals**: Expected to report a loss of $1.54 per share and revenues of $141.99 million, with growth driven by its lead drug Crysvita [10][11] - **Acadia Pharmaceuticals**: Anticipated earnings of 6 cents per share and revenues of $241.74 million, primarily from sales of Nuplazid for Parkinson's disease psychosis [12][13] - **Denali Therapeutics**: Expected loss of 71 cents per share and revenues of $8.3 million, with updates on pipeline programs anticipated during the earnings report [17][18] Earnings Surprise Potential - The Earnings ESP methodology indicates that stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have a high chance of delivering earnings surprises, with a success rate of up to 70% [4][5]

Core Viewpoint - Viatris (VTRS) is set to report its first-quarter 2025 results on May 8, 2025, with revenue estimates at $3.24 billion and earnings at $0.50 per share [1] Group 1: Revenue Performance by Segment - Growth in Developed Markets is expected to be driven by strong new product performance and generics, with revenue estimates at $1.9 billion [2][3] - Emerging Markets are likely to see growth from the expansion of the cardiovascular portfolio in Latin America and key markets like Turkey, India, and Brazil, with revenue estimates at $480 million [4] - Sales in JANZ (Japan, Australia, and New Zealand) are anticipated to be negatively impacted by government price regulations, with revenue estimates at $309 million [5] - Greater China may experience revenue growth due to demand for chronic disease management products, with estimates at $553 million [6] Group 2: Brand and Generic Performance - The brand business constitutes the majority of Viatris' portfolio, benefiting from cardiovascular portfolio expansion in Latin America and strong growth in Europe and Greater China [7] - Operating expenses are expected to rise due to investments in new product launches and R&D progress [7] Group 3: Stock Performance and Earnings History - Viatris' shares have declined by 31.2% over the past year, contrasting with a 1% decline in the industry [8] - The company has a mixed earnings surprise history, beating estimates in two of the last four quarters and missing in the other two, with an average surprise of 1.26% [9] Group 4: Earnings Prediction Model - The current model does not predict an earnings beat for Viatris, as it has a Zacks Rank of 4 (Sell) despite an Earnings ESP of +3.31% [10][11]

Core Viewpoint - Amgen is set to report its first-quarter 2025 results on May 1, with expectations of strong sales driven by volume growth in key products, although pricing pressures may impact overall revenue [1][4]. Sales Estimates - The Zacks Consensus Estimate for first-quarter sales is $7.96 billion, with earnings expected at $4.16 per share [1]. - Specific sales estimates for key products include Evenity at $406 million, Repatha at $616 million, Kyprolis at $381 million, and Blincyto at $333 million [2]. Patent Expiration Impact - Patents for Prolia and Xgeva expired in February 2025 in the U.S., leading to anticipated significant sales erosion due to biosimilar competition, with estimates of $990 million for Prolia and $542 million for Xgeva [3]. New Product Contributions - Newer drugs like Tezspire and Tavneos are expected to contribute positively to top-line growth, alongside the successful launch of Imdelltra for advanced small cell lung cancer [4]. Declining Sales of Established Products - Sales of Enbrel and Otezla are projected to decline due to price reductions and historical trends related to benefit plan changes and increased co-pay expenses [5][6]. Biosimilars Performance - Increased competition is expected to negatively impact revenues from oncology biosimilars, while sales of Amjevita/Amgevita are likely to have increased [7]. - Amgen launched biosimilars Wezlana and Pavblu, with investors keenly observing their sales performance [8]. Operating Margin Expectations - Amgen anticipates the lowest operating margin of the year at around 42% for the first quarter, with R&D costs expected to rise while SG&A costs as a percentage of sales are projected to decline [9]. Earnings Surprise History - Amgen has a strong earnings surprise history, beating estimates in the last four quarters with an average surprise of 5.23% [10]. Earnings Prediction Model - The current model does not predict a definitive earnings beat for Amgen, with an Earnings ESP of -0.05% and a Zacks Rank of 3 [12].

Core Viewpoint - Denali Therapeutics has initiated a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for Hunter syndrome, with expectations to complete the submission by May 2025 and a potential commercial launch in late 2025 or early 2026 [1][7]. Company Developments - The company is engaged in regular collaboration with the FDA's Center for Drug Evaluation and Research (CDER) regarding the BLA data package, including the use of cerebrospinal fluid heparan sulfate as a surrogate endpoint for accelerated approval [1][2]. - Denali's Chief Medical Officer expressed gratitude for the FDA's support and highlighted the importance of this regulatory milestone for the Hunter syndrome community [2]. - The company is also preparing for the development and approval path for DNL126, a treatment for Sanfilippo syndrome, under the START program with CDER [2][7]. Product Information - Tividenofusp alfa (DNL310) is designed to deliver the iduronate 2-sulfatase enzyme to the brain and body, addressing cognitive, behavioral, and physical symptoms of Hunter syndrome [4]. - The product has received Fast Track and Breakthrough Therapy designations from the FDA, as well as Priority Medicines designation from the European Medicines Agency [4]. - The ongoing Phase 2/3 COMPASS study is enrolling participants to support global approval, comparing tividenofusp alfa with idursulfase [5]. Disease Context - Hunter syndrome (MPS II) is a rare genetic disorder affecting over 2,000 individuals worldwide, primarily males, leading to various physical and cognitive symptoms due to a deficiency of the IDS enzyme [3]. - Current standard treatments only partially address physical symptoms and do not cross the blood-brain barrier, leaving cognitive and behavioral symptoms unmet [3].